More than $209 B in branded drug sales will go off-patent between 2011 and 2014 including big names - Advair, Viagra, Seroquel, Zyprexa, Symbicort, Singulair and Lexapro. Projections are that the generic market will reach $135-$150 B by 2015 as a result, representing a 9% CAGR.
GenMed CEO, Erwin Bouwens says, "The coming decade will be a period of agresive growth for companies positioned in the generic pharmaceuticals market. We plan to take full advantage of the opportunities to apply for additional drug licenses as they become available."
Posted by Bruce Lehr Jan 24th 2011.